Kelun-Biotech to Showcase Innovations at the 44th J.P. Morgan Healthcare Conference

Kelun-Biotech to Attend the 44th J.P. Morgan Healthcare Conference

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., commonly known as Kelun-Biotech, will be participating in the prestigious 44th J.P. Morgan Healthcare Conference, set to be held in San Francisco, California, from January 12 to 15, 2026. This annual gathering is renowned as a pivotal event for stakeholders and experts across the global healthcare arena, providing a vital platform for sharing insights, developments, and networking opportunities within the biopharmaceutical sector.

Conference Highlights

Dr. Michael Ge, the President and CEO of Kelun-Biotech, is scheduled to present on January 15, 2026, at 9:30 AM Pacific Standard Time at the Westin St. Francis in San Francisco. His presentation will focus not only on the recent advancements and achievements of Kelun-Biotech but also on innovative strategies that the company has adopted to enhance its position in the competitive biopharmaceutical market. The conference will feature numerous distinguished experts and industry leaders who will discuss the latest trends and breakthroughs in healthcare innovations.

Kelun-Biotech is particularly excited about this year's event, given the current transformative phase the global pharmaceutical industry is undergoing. The company plans to leverage this unique opportunity to forge strategic partnerships that could lead to mutually beneficial collaborations on an international scale.

About Kelun-Biotech

Kelun-Biotech (stock code 6990.HK) operates as a holding subsidiary of Kelun Pharmaceutical and is dedicated to the research, development, manufacturing, and global commercialization of innovative biologics and small molecules. The company addresses critical areas of medical need including solid tumors, autoimmune disorders, and metabolic diseases. With a strong emphasis on creating a globalized framework for drug development and industrialization, Kelun-Biotech is relentlessly focused on meeting unmet medical needs not only in China but worldwide.

To date, Kelun-Biotech is actively involved in over 30 key innovative drug projects, with 4 already receiving marketing approval. Moreover, one project is currently in the New Drug Application (NDA) stage, and more than 10 others are advancing through clinical trials. Notably, Kelun-Biotech has established one of the industry’s leading proprietary antibody-drug conjugate (ADC) and novel DC platforms known as OptiDC™, with 2 ADC projects currently available in the market and several others under various stages of clinical trials.

The participation of Kelun-Biotech in the J.P. Morgan Healthcare Conference signifies the company's commitment to leading advancements in healthcare and provides a clear channel for disseminating critical information about its innovations and future plans. For those interested in viewing the live presentation or accessing replays, additional details can be found on the 'Investor Relations - Investor Calendar' section of Kelun-Biotech's official website.

In conclusion, the upcoming conference is not just an opportunity for Kelun-Biotech to showcase its current advancements but also a significant milestone that could potentially reshape future collaborations and innovations within the biopharmaceutical landscape. The world is watching as Kelun-Biotech steps into the spotlight of one of the industry's most prestigious occasions.